North America Hepatitis C Market Report and Forecast 2025-2034

North America Hepatitis C Market Size

The global hepatitis C market was valued at USD 63.171 billion in 2024, with North America holding a significant market share. The market is driven by increased government initiatives and research funding for hepatitis C. It is expected to grow at a CAGR of 13.6% during the forecast period of 2025-2034, with the values likely to attain USD 199.63 billion by 2034.

North America Hepatitis C Market Outlook

• The market demand is driven by the rising burden of hepatitis C and the growing aging population more prone to contracting viral infections.

• One of the major North America hepatitis C market trends is the increased government initiatives focused on lowering the cost of treatment and expanding testing facilities. The National HCV Elimination Plan proposed by the White House in their budget for 2023-2034 is one such major initiative.

• Increased investment in research and development activities by pharmaceutical companies and research institutions to develop new therapies and improve existing ones is impacting the market share.

North America Hepatitis C Market Analysis

Hepatitis C is a viral infection caused by the Hepatitis C virus (HCV). It can lead to inflammation of the liver and can cause both acute and chronic illness. The initial infection with hepatitis C has few to no symptoms and is referred to as a silent killer. Direct-acting antivirals (DAAs) are the common medications prescribed for this viral infection, with the treatment plan often involving a combination of two or more DAAs. In North America, there is a growing investment in research initiatives by pharmaceutical companies and research institutions to develop new therapies and improve existing ones, which directly impacts the global hepatitis C market dynamics. Further, the continuous innovations in treatments and the advancements in diagnostic technologies are driving the North America hepatitis C market growth.

Hepatitis C is a serious health challenge in North America. In the United States, it ranks as the leading cause of liver failure and a major cause of liver transplants. Around 2.7 to 3.9 million individuals are estimated to be affected by chronic hepatitis C in the United States with nearly 17,000 new cases occurring every year in the region. The rising burden of this viral disease fuels the need for effective antiviral therapies and is a significant growth driver of the market. Moreover, the growing aging population more prone to contracting viral infections is likely to augment the North America hepatitis C market demand in the forecast period.

According to the Centers for Disease Control and Prevention (CDC) Report released in 2023, only 1 in 3 adults diagnosed with hepatitis C in the United States has been cured. To address this alarming trend, a National HCV Elimination Plan was proposed by the White House in their budget for 2023-2034. The 2024 budget allocated USD 12.3 billion to eliminate hepatitis C by next 10 years. By improving access to medical care and screening, the national plan is projected to save over 90,000 lives and almost USD 60 billion in healthcare costs by 2050. Such government initiatives focused on lowering the cost of treatment and expanding testing facilities are poised to boost the market share.

North America Hepatitis C Market Segmentation

The report offers a detailed analysis of the market based on the following segments:

North America Hepatitis C Market: Competitive Landscape

The key features of the market report include funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

Gilead Sciences, Inc.

This American research-based biopharmaceutical company has a prominent presence in the market. Since 2013, it has delivered four curative treatments for hepatitis C in a span of less than four years, treating more than 5 million people with their medications.

AbbVie Inc.

AbbVie Inc (AbbVie), a specialty biopharmaceutical company, heavily invests in research and development initiatives to create innovative treatments. Its drug MAVYRET® is FDA-approved to treat chronic hepatitis C virus (HCV) infection in adults.

Merck & Co., Inc.

Merck & Co., Inc., an American multinational pharmaceutical company, is actively engaged in the clinical development of effective therapies for hepatitis C. The company, in collaboration with the American Liver Foundation, works to raise awareness among U.S. veterans about chronic Hepatitis C.

Bristol Myers Squibb

Bristol Myers Squibb's novel direct-acting antiviral, daclatasvir, is proven to treat multiple genotypes of the hepatitis C virus. The company also raises awareness regarding the dangers of hepatitis B and hepatitis C.

Other players in the market include Johnson & Johnson, Roche Holding AG, Pfizer Inc., Novartis AG, Vertex Pharmaceuticals, and Boehringer Ingelheim.

Key Highlights of the Report

North America Hepatitis C Market Report Snapshots

North America Hepatitis C Market Size

North America Hepatitis C Market Analysis

North America Hepatitis C Companies